Bayer Partners with Canada's PHRI to Evaluate COVID-19 Treatments
Bayer (Berlin, Germany) has announced that its Canadian organization Bayer Inc. (Mississauga, ON) will partner with the Population Health Research Institute (PHRI, Hamilton, ON) in launching a major clinical research program aimed at identifying potential treatments against COVID-19. The two studies will evaluate the safety and efficacy of different combination therapies including Bayer’s chloroquine and interferon beta-1b. Bayer will make a financial commitment of CAD 1.5 million (approx. €1 million) towards the studies and will supply study drugs to support the research. This adds to the CAD 0.5 million committed by the PHRI earlier this month which enabled the development of the research program. PHRI plans to enroll 6,000 patients into the two studies from more than 60 contributing research sites across the Canadian province of Ontario and internationally.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
